
MS Treatment Guidelines and Payer Step Therapy: Finding Balance
Existing MS guidelines are outdated and rarely used, while payers seek algorithms that individualized care cannot supply. The panel argues that early access to high-efficacy therapy should be a guiding principle.
Episodes in this series

In "MS Treatment Guidelines and Payer Step Therapy: Finding Balance," the panel weighs what current guidelines offer and how payer tiering affects patients.
Dr. Nair asks whether MS guidelines address the role of disease-modifying therapies, noting that payers frequently ask where such guidelines are. Dr. Newsome says guidelines exist from organizations such as the American Academy of Neurology, and the European community has another that serves as a roadmap.
Dr. Freeman observes that payers want an algorithm, but MS care is as much art as science. Every clinician carries a mental algorithm and diverges from it constantly. Dr. Longbrake adds that every patient's MS is that patient's MS, so treatment must reflect an individual experience even when lesion burden looks similar.
Dr. Nair pushes back. When payers require patients to fail two drugs before reaching high efficacy, time is brain.
Dr. Newsome replies that within tiered systems, clinicians can usually find reasons a patient cannot take the payer-preferred drug. Dr. Freeman says denial notices often require failing several drugs. She argues that every person with MS should have access to high-efficacy therapy early as a first line, and that every formulary should reflect that principle.
Dr. Newsome notes that free-drug programs can start therapy and build the case for coverage. Dr. Freeman adds that preventing early accumulation of disease protects brain reserve against progression.
Our next episode, "BTK Inhibitors in MS: Mechanism, CNS Penetrance, and Binding Differences," begins the discussion of BTK inhibitors with Dr. Longbrake and Dr. Freeman.
Related to this article








